Vladimir Coric, MD
Research & Publications
Biography
News
Coauthors
Selected Publications
- Ataxia Rating Scales Reflect Patient Experience: an Examination of the Relationship Between Clinician Assessments of Cerebellar Ataxia and Patient-Reported OutcomesPotashman M, Mize M, Beiner M, Pierce S, Coric V, Schmahmann J. Ataxia Rating Scales Reflect Patient Experience: an Examination of the Relationship Between Clinician Assessments of Cerebellar Ataxia and Patient-Reported Outcomes. The Cerebellum 2022, 22: 1257-1273. PMID: 36495470, PMCID: PMC10657309, DOI: 10.1007/s12311-022-01494-1.
- Health State Utility Mapping of Rimegepant for the Preventive Treatment of Migraine: Double-Blind Treatment Phase and Open Label Extension (BHV3000-305)Powell L, L’Italien G, Popoff E, Johnston K, O’Sullivan F, Harris L, Croop R, Coric V, Lipton R. Health State Utility Mapping of Rimegepant for the Preventive Treatment of Migraine: Double-Blind Treatment Phase and Open Label Extension (BHV3000-305). Advances In Therapy 2022, 40: 585-600. PMID: 36417057, PMCID: PMC9898331, DOI: 10.1007/s12325-022-02369-x.
- Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double‐blind, randomized, placebo‐controlled, dose‐ranging trialCroop R, Madonia J, Stock D, Thiry A, Forshaw M, Murphy A, Coric V, Lipton R. Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double‐blind, randomized, placebo‐controlled, dose‐ranging trial. Headache The Journal Of Head And Face Pain 2022, 62: 1153-1163. PMID: 36239038, PMCID: PMC9827820, DOI: 10.1111/head.14389.
- Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/HarmJohnston K, Powell L, Popoff E, Harris L, Croop R, Coric V, L’Italien G. Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm. The Clinical Journal Of Pain 2022, 38: 680-685. PMID: 36125279, PMCID: PMC9555761, DOI: 10.1097/ajp.0000000000001072.
- A stated preference survey to explore patient preferences for novel preventive migraine treatmentsHubig L, Smith T, Chua G, Lloyd A, Powell L, Johnston K, Harris L, L'Italien G, Coric V, Lo S. A stated preference survey to explore patient preferences for novel preventive migraine treatments. Headache The Journal Of Head And Face Pain 2022, 62: 1187-1197. PMID: 36047857, PMCID: PMC9826196, DOI: 10.1111/head.14386.
- Measuring interictal burden among people affected by migraine: a descriptive survey studyHubig L, Smith T, Williams E, Powell L, Johnston K, Harris L, L’Italien G, Coric V, Lloyd A, Lo S. Measuring interictal burden among people affected by migraine: a descriptive survey study. The Journal Of Headache And Pain 2022, 23: 97. PMID: 35941572, PMCID: PMC9358846, DOI: 10.1186/s10194-022-01467-z.
- Real-World experience of interictal burden and treatment in migraine: a qualitative interview studyLo S, Gallop K, Smith T, Powell L, Johnston K, Hubig L, Williams E, Coric V, Harris L, L’Italien G, Lloyd A. Real-World experience of interictal burden and treatment in migraine: a qualitative interview study. The Journal Of Headache And Pain 2022, 23: 65. PMID: 35676636, PMCID: PMC9174626, DOI: 10.1186/s10194-022-01429-5.
- Real‐world assessment of the relationship between migraine‐related disability and healthcare costs in the United StatesHarris L, L’Italien G, Kumar A, Seelam P, LaVallee C, Coric V, Lipton R. Real‐world assessment of the relationship between migraine‐related disability and healthcare costs in the United States. Headache The Journal Of Head And Face Pain 2022, 62: 473-481. PMID: 35343590, PMCID: PMC9313575, DOI: 10.1111/head.14289.
- P‐Glycoprotein and Breast Cancer Resistance Protein Transporter Inhibition by Cyclosporine and Quinidine on the Pharmacokinetics of Oral Rimegepant in Healthy SubjectsBhardwaj R, Collins J, Stringfellow J, Madonia J, Anderson M, Finley J, Stock D, Coric V, Croop R, Bertz R. P‐Glycoprotein and Breast Cancer Resistance Protein Transporter Inhibition by Cyclosporine and Quinidine on the Pharmacokinetics of Oral Rimegepant in Healthy Subjects. Clinical Pharmacology In Drug Development 2022, 11: 889-897. PMID: 35304977, PMCID: PMC9311059, DOI: 10.1002/cpdd.1088.
- Human Milk and Plasma Pharmacokinetics of Single-Dose Rimegepant 75 mg in Healthy Lactating WomenBaker T, Croop R, Kamen L, Price P, Stock D, Ivans A, Bhardwaj R, Anderson M, Madonia J, Stringfellow J, Bertz R, Coric V, Hale T. Human Milk and Plasma Pharmacokinetics of Single-Dose Rimegepant 75 mg in Healthy Lactating Women. Breastfeeding Medicine 2022, 17: 277-282. PMID: 35049333, PMCID: PMC8972016, DOI: 10.1089/bfm.2021.0250.
- Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201)Johnston K, Harris L, Powell L, Popoff E, Coric V, L’Italien G, Schreiber C. Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201). The Journal Of Headache And Pain 2022, 23: 10. PMID: 35038983, PMCID: PMC8903552, DOI: 10.1186/s10194-021-01378-5.
- POSC170 Decreased Opioid Use in Migraine Patients Following Rimegepant Initiation: A Real-World AnalysisMohajer A, Scripture J, Harris L, Rosen N, Coric V, Croop R, L'Italien G. POSC170 Decreased Opioid Use in Migraine Patients Following Rimegepant Initiation: A Real-World Analysis. Value In Health 2022, 25: s134. DOI: 10.1016/j.jval.2021.11.644.
- POSC202 Estimated Migraine Patient Population in England Progressing Beyond First-Line Acute ManagementHarris L, L'Italien G, Croop R, Coric V, Robbins J, Woolley J, OConnell T. POSC202 Estimated Migraine Patient Population in England Progressing Beyond First-Line Acute Management. Value In Health 2022, 25: s140. DOI: 10.1016/j.jval.2021.11.675.
- Rimegepant 75 mg for acute treatment of migraine is associated with significant reduction in monthly migraine days: Results from a long-term, open-label studyL’Italien G, Popoff E, Johnston K, McGrath D, Conway C, Powell L, Harris L, Kowalczyk N, Croop R, Coric V. Rimegepant 75 mg for acute treatment of migraine is associated with significant reduction in monthly migraine days: Results from a long-term, open-label study. Cephalalgia Reports 2022, 5: 25158163221075596. DOI: 10.1177/25158163221075596.
- Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving RimegepantJohnston K, L’Italien G, Popoff E, Powell L, Croop R, Thiry A, Harris L, Coric V, Lipton R. Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant. Advances In Therapy 2021, 38: 5209-5220. PMID: 34455556, PMCID: PMC8478726, DOI: 10.1007/s12325-021-01897-2.
- Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysisJohnston K, Popoff E, Deighton A, Dabirvaziri P, Harris L, Thiry A, Croop R, Coric V, L’Italien G, Moren J. Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis. Expert Review Of Pharmacoeconomics & Outcomes Research 2021, 22: 155-166. PMID: 34148501, DOI: 10.1080/14737167.2021.1945444.
- Matching‐adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health‐related quality of life in the treatment of migrainePopoff E, Johnston K, Croop R, Thiry A, Harris L, Powell L, Coric V, L’Italien G, Moren J. Matching‐adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health‐related quality of life in the treatment of migraine. Headache The Journal Of Head And Face Pain 2021, 61: 906-915. PMID: 34021585, PMCID: PMC8361942, DOI: 10.1111/head.14128.
- Novel acute therapies in the treatment of migraine: impact of re-dosing on cost–utility outcomesJohnston K, L'italien G, Harris L, Deighton A, Popoff E, Croop R, Coric V. Novel acute therapies in the treatment of migraine: impact of re-dosing on cost–utility outcomes. Journal Of Medical Economics 2021, 24: 512-513. PMID: 33843409, DOI: 10.1080/13696998.2021.1915600.
- A phase 1 randomized study of hemodynamic effects and pharmacokinetic interactions during concomitant use of rimegepant and sumatriptan in healthy adultsCroop R, Ivans A, Anderson M, Stringfellow J, Bertz R, Hanna M, Healy F, Stock D, Coric V, Lipton R. A phase 1 randomized study of hemodynamic effects and pharmacokinetic interactions during concomitant use of rimegepant and sumatriptan in healthy adults. Cephalalgia Reports 2021, 4: 25158163211007922. DOI: 10.1177/25158163211007922.
- Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trialCroop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM, Stock EG, Coric V, Goadsby PJ. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. The Lancet 2020, 397: 51-60. PMID: 33338437, DOI: 10.1016/s0140-6736(20)32544-7.
- Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for MigraineBerman G, Croop R, Kudrow D, Halverson P, Lovegren M, Thiry A, Conway C, Coric V, Lipton R. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine. Headache The Journal Of Head And Face Pain 2020, 60: 1734-1742. PMID: 32799325, PMCID: PMC7496574, DOI: 10.1111/head.13930.
- Assessing Effects of BHV-0223 40 mg Zydis Sublingual Formulation and Riluzole 50 mg Oral Tablet on Liver Function Test Parameters Utilizing DILIsymLongo D, Shoda L, Howell B, Coric V, Berman R, Qureshi I. Assessing Effects of BHV-0223 40 mg Zydis Sublingual Formulation and Riluzole 50 mg Oral Tablet on Liver Function Test Parameters Utilizing DILIsym. Toxicological Sciences 2020, 175: 292-300. PMID: 32040174, PMCID: PMC7253195, DOI: 10.1093/toxsci/kfaa019.
- Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapyMullin K, Kudrow D, Croop R, Lovegren M, Conway C, Coric V, Lipton R. Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy. Neurology 2020, 94: 10.1212/wnl.0000000000008944. PMID: 31932515, PMCID: PMC7526667, DOI: 10.1212/wnl.0000000000008944.
- Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trialCroop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, Coric V, Lipton RB. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. The Lancet 2019, 394: 737-745. PMID: 31311674, DOI: 10.1016/s0140-6736(19)31606-x.
- Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for MigraineLipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, Dubowchik GM, Conway CM, Coric V, Goadsby PJ. Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine. New England Journal Of Medicine 2019, 381: 142-149. PMID: 31291516, DOI: 10.1056/nejmoa1811090.
- Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical TrialCoric V, Salloway S, van Dyck CH, Dubois B, Andreasen N, Brody M, Curtis C, Soininen H, Thein S, Shiovitz T, Pilcher G, Ferris S, Colby S, Kerselaers W, Dockens R, Soares H, Kaplita S, Luo F, Pachai C, Bracoud L, Mintun M, Grill JD, Marek K, Seibyl J, Cedarbaum JM, Albright C, Feldman HH, Berman RM. Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial. JAMA Neurology 2015, 72: 1324-1333. PMID: 26414022, DOI: 10.1001/jamaneurol.2015.0607.
- Efficacy of Modified Cognitive Interviewing, Compared to Human Judgments in Detecting Deception Related to Bio-threat ActivitiesMorgan C, Rabinowitz Y, Hilts D, Weller C, Coric V. Efficacy of Modified Cognitive Interviewing, Compared to Human Judgments in Detecting Deception Related to Bio-threat Activities. Journal Of Strategic Security 2013, 6: 100-119. DOI: 10.5038/1944-0472.6.3.9.
- Sheehan Suicidality Tracking Scale (S-STS): Reliability, convergent and discriminative validity in young Italian adultsPreti A, Sheehan D, Coric V, Distinto M, Pitanti M, Vacca I, Siddi A, Masala C, Petretto D. Sheehan Suicidality Tracking Scale (S-STS): Reliability, convergent and discriminative validity in young Italian adults. Comprehensive Psychiatry 2013, 54: 842-849. PMID: 23618606, DOI: 10.1016/j.comppsych.2013.03.012.
- Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer DiseaseCoric V, van Dyck CH, Salloway S, Andreasen N, Brody M, Richter RW, Soininen H, Thein S, Shiovitz T, Pilcher G, Colby S, Rollin L, Dockens R, Pachai C, Portelius E, Andreasson U, Blennow K, Soares H, Albright C, Feldman HH, Berman RM. Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease. JAMA Neurology 2012, 69: 1430-1440. PMID: 22892585, DOI: 10.1001/archneurol.2012.2194.
- Multicenter, randomized, double‐blind, active comparator and placebo‐controlled trial of a corticotropin‐releasing factor receptor‐1 antagonist in generalized anxiety disorderCoric V, Feldman HH, Oren DA, Shekhar A, Pultz J, Dockens RC, Wu X, Gentile KA, Huang S, Emison E, Delmonte T, D'Souza BB, Zimbroff DL, Grebb JA, Goddard AW, Stock EG. Multicenter, randomized, double‐blind, active comparator and placebo‐controlled trial of a corticotropin‐releasing factor receptor‐1 antagonist in generalized anxiety disorder. Depression And Anxiety 2010, 27: 417-425. PMID: 20455246, DOI: 10.1002/da.20695.
- Sheehan Suicidality Tracking Scale (Sheehan-STS): Preliminary Results from a Multicenter Clinical Trial in Generalized Anxiety Disorder.Coric V, Stock EG, Pultz J, Marcus R, Sheehan DV. Sheehan Suicidality Tracking Scale (Sheehan-STS): Preliminary Results from a Multicenter Clinical Trial in Generalized Anxiety Disorder. Innov Clin Neurosci 2009, 6: 26-31. PMID: 19724740, PMCID: PMC2719443.
- Response to Chamberlain et al. Re: Systematic Review: Pharmacological and Behavioral Treatments for TrichotillomaniaBloch M, Landeros-Weisenberger A, Dombrowski P, Nudel J, Pittenger C, Leckman J, Kelmendi B, Wegner R, Coric V. Response to Chamberlain et al. Re: Systematic Review: Pharmacological and Behavioral Treatments for Trichotillomania. Biological Psychiatry 2008, 63: e34-e35. DOI: 10.1016/j.biopsych.2008.01.022.
- Systematic Review: Pharmacological and Behavioral Treatment for TrichotillomaniaBloch MH, Landeros-Weisenberger A, Dombrowski P, Kelmendi B, Wegner R, Nudel J, Pittenger C, Leckman JF, Coric V. Systematic Review: Pharmacological and Behavioral Treatment for Trichotillomania. Biological Psychiatry 2007, 62: 839-846. PMID: 17727824, DOI: 10.1016/j.biopsych.2007.05.019.
- Erratum: A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorderBloch M, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken M, Leckman J. Erratum: A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular Psychiatry 2006, 11: 795-795. DOI: 10.1038/sj.mp.4001859.
- Initial evidence of the beneficial effects of glutamate-modulating agents in the treatment of self-injurious behavior associated with borderline personality disorder.Pittenger C, Krystal JH, Coric V. Initial evidence of the beneficial effects of glutamate-modulating agents in the treatment of self-injurious behavior associated with borderline personality disorder. The Journal Of Clinical Psychiatry 2005, 66: 1492-3. PMID: 16420092, DOI: 10.4088/jcp.v66n1121d.
- Riluzole Augmentation in Treatment-Resistant Obsessive–Compulsive Disorder: An Open-Label TrialCoric V, Taskiran S, Pittenger C, Wasylink S, Mathalon DH, Valentine G, Saksa J, Wu YT, Gueorguieva R, Sanacora G, Malison RT, Krystal JH. Riluzole Augmentation in Treatment-Resistant Obsessive–Compulsive Disorder: An Open-Label Trial. Biological Psychiatry 2005, 58: 424-428. PMID: 15993857, DOI: 10.1016/j.biopsych.2005.04.043.
- 231. Neuroendocrine and psychobiological responses to uncontrollable stressMorgan C, Coric V, Zimolo Z, Hoyt G, Wang S, Hazlett G, Charney D. 231. Neuroendocrine and psychobiological responses to uncontrollable stress. Biological Psychiatry 2000, 47: s70. DOI: 10.1016/s0006-3223(00)00495-9.
- 459. Psycho-biological indices of special operations selectionMorgan C, Simpson P, Hazlett G, Coric V, Charney D. 459. Psycho-biological indices of special operations selection. Biological Psychiatry 2000, 47: s140. DOI: 10.1016/s0006-3223(00)00729-0.
- Carbon monoxide poisoning and treatment with hyperbaric oxygen in the subacute phaseCoric V, Oren D, Wolkenberg F, Kravitz R. Carbon monoxide poisoning and treatment with hyperbaric oxygen in the subacute phase. Journal Of Neurology Neurosurgery & Psychiatry 1998, 65: 245. PMID: 9703180, PMCID: PMC2170185, DOI: 10.1136/jnnp.65.2.245.